Dupixent eosinophilic esophagitis approval in children predicted
The news just keeps on coming on Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) immunology blockbuster Dupixent (dupilumab).
Recent updates have included its approval by the European Commission for children aged six to 11 years with severe asthma with type 2 inflammation and the US Food and Drug Administration (FDA) accepting a Priority Review of the supplemental Biologics License Application (sBLA) in patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.
"The launch of high-price Dupixent for adolescents and adults is expected to increase sales in this space significantly"Data and analytics company GlobalData has predicted that Dupixent will likely see a label expansion to young EoE patients soon after approval in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze